CMS Makes Initial Drug Price Offers, Highlights New IRA Research

By Gabrielle Wanneh, Maaisha Osman / February 1, 2024 at 5:12 PM

CMS has submitted its initial lower price offers to drug makers for the 10 Part-D drugs selected for the program’s inaugural round of price negotiations in Medicare, along with a justification of the agency’s price and decision-making, HHS said Thursday (Feb. 1), prompting outcry from the brand drug lobby that the price offers were made behind closed doors, are politically motivated and don’t account for the true value of drugs.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.